CHMP positive recommendation for Amvuttra (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy – Alnylam Pharma
Alnylam Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of its RNAi therapeutic… read more.
